The CV benefit of statins can be partly explained by their ability to inhibit of HMG-CoA reductase, which subsequently lowers cholesterol and decreases the formation of mevalonate. However ...

Adding mevalonate prevented ApoA1 induction by statins. This suggests that a statin's action on ApoA1 secretion depends on inhibition of HMG-CoA reductase. [20] However, other actions may ...

The statins lower LDL-C by inhibiting an enzyme, HMG-CoA reductase, that catalyzes the rate-limiting step in the synthesis of mevalonate, a cholesterol precursor. This results in reduction of ...